
News|Videos|June 16, 2024
Comparative Efficacy of Bruton Tyrosine Kinase Inhibitors in the Treatment of Relapsed/Refractory Chronic Lymphocytic Leukemia: A Network Meta-Analysis
Author(s)Mazyar Shadman, MD, MPH
This is an evaluation of the results of a network meta-analysis covering the comparative efficacy of bruton tyrosine kinase Inhibitors in relapse/refractory chronic lymphocytic leukemia.
Advertisement
Advertisement
Latest CME
Advertisement
Advertisement
Trending on OncLive
1
Long-Term Cilta-Cel Data Show Low Rates of PFS Events in Standard-Risk R/R Myeloma
2
Nonresponse to Bridging Therapy and Peak ALC After Cilta-Cel Are Associated With Neurotoxicity, NRM in Myeloma
3
FDA Updates Axi-Cel Label to Remove Limitation of Use in R/R PCNSL
4
Real-World Data Support Clinical Benefit With Lifileucel in Previously Treated Advanced Melanoma
5




































